Table 2.

Adverse events of IL-13-PE in patients treated at 1 and 2 μg/kg.

Common toxicity criteria term	1 μg/kg (N = 6)		2 μg/kg (N = 2)
	Grade 1 or 2	Grade 3 or 4	Grade 1 or 2	Grade 3 or 4
	N (%)	N (%)	N (%)	N (%)
Anemia	3 (50)	0	2 (100)	2 (100)
Proteinuria	3 (50)	0	2 (100)	1 (50)
Alanine aminotransferase increased	2 (33.3)	0	1 (50)	0
Aspartate aminotransferase increased	2 (33.3)	0	1 (50)	0
Creatinine increased	2 (33.3)	0	2 (100)	1 (50)
Fatigue	2 (33.3)	0	1 (50)	0
Alkaline phosphatase increased	1 (16.7)	0	0	0
Chills	1 (16.7)	0	0	0
Cough	1 (16.7)	0	0	0
Dyspnea	1 (16.7)	0	0	0
Edema limbs	1 (16.7)	0	1 (50)	0
Electrocardiogram QT corrected interval prolonged	1 (16.7)	0	0	0
Headache	1 (16.7)	0	1 (50)	0
Hyperkalemia	1 (16.7)	0	0	0
Hypertension	1 (16.7)	1 (16.7)	0	0
Pericardial effusion	1 (16.7)	0	0	0
Weight gain	1 (16.7)	0	1 (50)	0
Acute kidney injury	0	0	2 (100)	1 (50)
Blood bilirubin increased	0	0	1 (50)	0
Bruising	0	0	1 (50)	0
Epistaxis	0	0	1 (50)	0
Fall	0	0	1 (50)	0
Hematuria	0	0	2 (100)	0
Hypoalbuminemia	0	0	2 (100)	0
Hypocalcemia	0	0	1 (50)	0
Hypokalemia	0	0	2 (100)	0
Hypomagnesemia	0	0	1 (50)	0
Hyponatremia	0	0	1 (50)	1 (50)
Neutropenia	0	0	1 (50)	1 (50)
Nausea	0	0	1 (50)	0
Pain	0	0	0	1 (50)
Thrombocytopenia	0	0	2 (100)	1 (50)

IL-13-PE, interleukin-13-Pseudomonas exotoxin.